Distribution of CDKN2B, CDKN1A, and CDKN1B promoter haplotypes in patients with pre-B ALL and controls
| Gene, Haplotype . | DNA Variant . | No. (%) . | OR (95% CI) . | P . | |||
|---|---|---|---|---|---|---|---|
| Variant 1 . | Variant 2 . | Variant 3 . | ALL patients . | Controls . | |||
| CDKN2B* | −1270C>T | −593A>T,C | −287G>C | ||||
| 2B-1 | C | A | C | 189 (41.4) | 242 (43.7) | 0.9 (0.7-1.2) | .48 |
| 2B-2 | C | T | G | 144 (31.6) | 210 (37.9) | 0.8 (0.6-1.0) | .04 |
| 2B-3 | C | A | G | 92 (20.2) | 73 (13.2) | 1.7 (1.2-2.4) | .004§ |
| 2B-4 | T | A | G | 13 (2.9) | 17 (3.1) | 0.9 (0.4-2.0) | > .999 |
| 2B-5 | C | C | G | 11 (2.4) | 12 (2.2) | 1.1 (0.4-2.8) | .83 |
| 2B-6 | T | A | C | 7 (1.5) | 0 (0) | — | — |
| CDKN1A† | −1284T>C | −899T>G | −791T>C | ||||
| 1A-1 | T | T | T | 234 (57.9) | 322 (59.4) | 1.0 (0.8-1.3) | > .999 |
| 1A-2 | C | G | C | 78 (19.3) | 111 (20.5) | 1.0 (0.7-1.3) | .81 |
| 1A-3 | C | T | C | 71 (17.6) | 76 (14.0) | 1.3 (0.9-1.9) | .10 |
| 1A-4 | T | G | C | 16 (4.0) | 24 (4.4) | 0.9 (0.4-1.8) | .87 |
| 1A-5 | T | G | T | 1 (0.2) | 6 (1.1) | 0.2 (0.004-1.9) | .25 |
| 1A-6 | C | T | T | 3 (0.7) | 3 (0.5) | 1.4 (0.2-10.3) | .70 |
| 1A-7 | C | G | T | 1 (0.2) | 0 (0) | — | — |
| CDKN1B‡ | −1857C>T | −1608G>A | −373G>T | ||||
| 1B-1 | C | G | T | 189 (40.4) | 238 (43.0) | 0.9 (0.7-1.1) | .25 |
| 1B-2 | C | G | G | 190 (40.4) | 215 (38.8) | 1.0 (0.8-1.3) | .85 |
| 1B-3 | C | A | G | 50 (10.6) | 45 (8.1) | 1.3 (0.8-2.1) | .23 |
| 1B-4 | T | G | G | 40 (8.5) | 56 (10.1) | 0.8 (0.5-1.3) | .33 |
| 1B-5 | T | G | T | 1 (0.2) | 0 (0) | — | — |
| Gene, Haplotype . | DNA Variant . | No. (%) . | OR (95% CI) . | P . | |||
|---|---|---|---|---|---|---|---|
| Variant 1 . | Variant 2 . | Variant 3 . | ALL patients . | Controls . | |||
| CDKN2B* | −1270C>T | −593A>T,C | −287G>C | ||||
| 2B-1 | C | A | C | 189 (41.4) | 242 (43.7) | 0.9 (0.7-1.2) | .48 |
| 2B-2 | C | T | G | 144 (31.6) | 210 (37.9) | 0.8 (0.6-1.0) | .04 |
| 2B-3 | C | A | G | 92 (20.2) | 73 (13.2) | 1.7 (1.2-2.4) | .004§ |
| 2B-4 | T | A | G | 13 (2.9) | 17 (3.1) | 0.9 (0.4-2.0) | > .999 |
| 2B-5 | C | C | G | 11 (2.4) | 12 (2.2) | 1.1 (0.4-2.8) | .83 |
| 2B-6 | T | A | C | 7 (1.5) | 0 (0) | — | — |
| CDKN1A† | −1284T>C | −899T>G | −791T>C | ||||
| 1A-1 | T | T | T | 234 (57.9) | 322 (59.4) | 1.0 (0.8-1.3) | > .999 |
| 1A-2 | C | G | C | 78 (19.3) | 111 (20.5) | 1.0 (0.7-1.3) | .81 |
| 1A-3 | C | T | C | 71 (17.6) | 76 (14.0) | 1.3 (0.9-1.9) | .10 |
| 1A-4 | T | G | C | 16 (4.0) | 24 (4.4) | 0.9 (0.4-1.8) | .87 |
| 1A-5 | T | G | T | 1 (0.2) | 6 (1.1) | 0.2 (0.004-1.9) | .25 |
| 1A-6 | C | T | T | 3 (0.7) | 3 (0.5) | 1.4 (0.2-10.3) | .70 |
| 1A-7 | C | G | T | 1 (0.2) | 0 (0) | — | — |
| CDKN1B‡ | −1857C>T | −1608G>A | −373G>T | ||||
| 1B-1 | C | G | T | 189 (40.4) | 238 (43.0) | 0.9 (0.7-1.1) | .25 |
| 1B-2 | C | G | G | 190 (40.4) | 215 (38.8) | 1.0 (0.8-1.3) | .85 |
| 1B-3 | C | A | G | 50 (10.6) | 45 (8.1) | 1.3 (0.8-2.1) | .23 |
| 1B-4 | T | G | G | 40 (8.5) | 56 (10.1) | 0.8 (0.5-1.3) | .33 |
| 1B-5 | T | G | T | 1 (0.2) | 0 (0) | — | — |
The risk of ALL was evaluated for each haplotype compared with all other possible haplotypes combined. The χ2 values represent overall haplotype frequency comparisons between ALL patients and control subjects for each gene. Percentages indicate number of chromosomes with given haplotype/total number of chromosomes.
OR indicates crude odds ratio; df, degrees of freedom; and —, not applicable.
χ2df=5 = 19.1, P < .001.
χ2df=6 = 5.0, P = .59.
χ2df=4 = 3.7, P = .44.
Remained significant following multiple test correction with an FDR of 10%.